Fact-sheet: Hereditary hemorrhagic telangiectasia - Rendu-Osler-Weber syndrome


Updated on 02/14/2025 at 12:14 PM

Note : 0/10

View all RADEOS cases associated with this fact-sheet

Definition

Rendu-Osler disease, or Hereditary Hemorrhagic Telangiectasia (HHT), is a vascular disease (vascular dysplasia) belonging to the phakomatoses, of autosomal dominant genetic origin with variable penetrance, characterized by the development of telangiectasias and arteriovenous malformations (AVMs) or fistulas.
Frequency of 1/8000.
Three responsible genes:
- endoglin (ENG), which encodes the TGF-beta coreceptor: predominant pulmonary involvement
- activin receptor-like kinase 1 (ACVRL1/ALK-1), which encodes one of the TGF-beta receptor dimers in endothelial cells: predominant hepatic involvement
- SMAD4, rarer (1-3%), associated with combined Rendu-Osler disease and juvenile colorectal polyposis (<4% of cases)

Clinical features

Clinical diagnosis is based on the 4 Curaçao criteria

  • spontaneous or recurrent epistaxis
  • cutaneous or mucosal telangiectasias (lips, tongue, fingers)
  • family history: at least one first-degree relative affected, diagnosed according to these same criteria
  • visceral AVMs: pulmonary, hepatic, gastrointestinal, cerebral, spinal

Definite if 3 or 4 criteria present
Possible if 2 criteria present
Unlikely if 1 criterion present
Epistaxis:

  • occurring in childhood, triggered by minor factors
  • recurrence and severity: iron-deficiency anemia, transfusion, impact on quality of life

Telangiectasias: cutaneous, mucosal, visceral

  • round, red capillary dilations surrounded by small star-shaped vessels

Right-to-left shunt:

  • dyspnea, platypnea, orthodeoxia
  • hypoxia, digital clubbing

Paradoxical embolism:

  • risk if feeding artery > 3 mm
  • thromboembolic, gaseous (stroke, TIA), septic (abscess)

Rupture:

  • favored during pregnancy due to increased cardiac output
  • intrabronchial: hemoptysis
  • intrapleural: hemothorax

Laboratory findings

Diagnosis confirmed by genetic testing

Ultrasound

Dilatation of the hepatic artery diameter > 6 mm

Increased systolic velocities > 80 cm/sec

Decreased resistive index < 0.55

Alteration of portal, arterial, and hepatic venous flow

Dilatation of the hepatic veins and/or main portal vein

CT

Pulmonary involvement:
20 to 50% of cases
Arteriovenous malformation (AVM) ++ and telangiectasias,
particularly in ENG and SMAD4 mutations
One or more enlarged feeding arteries supplying a serpiginous structure (fistula), from which an enlarged efferent pulmonary vein emerges.
3 types of fistulas:

  • simple: 1 feeding artery
  • complex segmental: 2 or more feeding arteries arising from a single hepatic segment
  • complex multisegmental: 2 or more feeding arteries arising from multiple segments

Hepatic involvement:

  • Abnormal intrahepatic communications or shunts between the hepatic arteries, the portal system, and the hepatic veins Arteriohepatic venous shunt: communication between hepatic artery branches and hepatic veins
  • Arterioportal shunt: communication between hepatic arteries and the portal system, Portal hypertension
  • Portohepatic venous shunt: communication between portal branches and hepatic veins, vascular steal of the hepatic parenchyma
  • Increased caliber or flow velocities of the hepatic arteries: > 6 mm, high-flow aneurysm, atheromatous lesions
  • Telangiectasias
  • Tumor or pseudotumor: regenerative nodules, FNH, hemangiomas
  • Perfusion abnormality: heterogeneous hepatic enhancement
  • Ischemia/necrosis, hepatic abscesses, and biliary lesions

Splenic involvement

  • Arterial abnormalities: increased caliber
  • ectasias
  • intra- or extrasplenic aneurysms
  • Parenchymal abnormalities: telangiectasias
  • angiomatous mass
  • fistulas

Pancreatic involvement: Telangiectasias and arteriovenous fistulas
Cerebral involvement:

  • Primary involvement (5-20%): AVM
  • Telangiectasias
  • Cavernoma
  • Secondary involvement: stroke ++
  • Abcess of brain
  • Portosystemic shunt (manganese deposition, pallidal T1 hyperintensity)

Gastrointestinal involvement;

  • 20% of patients (80-90% gastric involvement)
  • Bleeding risk ++

Vascular intervention

ENT embolization: may be indicated for frequent, disabling episodes of epistaxis, using microparticles (500-700 microns), as distally as possible to preserve the pedicles supplying the nasal fossae in case repeat embolizations are needed

Embolization of pulmonary AVMs

Differential diagnosis

  • Limited cutaneous systemic sclerosis
  • Gastrointestinal angiodysplasia
  • Isolated pulmonary, hepatic, or cerebral AVM
  • Other vascular disease responsible for AVMs
  • Hereditary benign telangiectasia
  • Other causes of recurrent epistaxis (coagulation disorders, other nasal mucosal disease)